					Breakthrough		
					therapy	Priority	Date and price of acquisition if the
Manufacturer				Estimated volume of patients	designation?	Review?	drug was not developed by the
Name	NDC	Name of Prescription Drug	A description of the marketing and pricing plans used in the launch of the new drug	who may be prescribed drug	(Y/N)	(Y/N)	manufacturer else N/A
			Disease awareness materials were created for HCPs and patients, as well as branded marketing				
			materials for HCPs and patients. Pricing research was performed to understand average cost of				
			the rare disease landscape as well as competitive landscape. Payer research was also performed				
Chiesi USA	10122031002 Filsuvez		to confirm relative Filsuvez price points.	132	N	Υ	N/A